• 1
    American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011.
  • 2
    Altekruise SF, Kosary CL, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2007 [based on November 2009 SEER data submission, posted to the SEER website 2010]. Bethesda, MD: National Cancer Institute; 2009. Available from: Accessed January 3, 2012.
  • 3
    Gupta S, Kong W, Peng Y, Miao Q, Mackillop WJ. Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int J Cancer. 2009; 125: 2159-2165.
  • 4
    Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92: 675-677.
  • 5
    Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29: 4294-4301.
  • 6
    Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100: 261-269.
  • 7
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guild lines in Oncology: Head and Neck Cancers. Version 1.2001. Fort Washington, PA: NCCN; 2009. Available from: Accessed January 3, 2012.]
  • 8
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567-578.
  • 9
    Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359: 1116-1127.
  • 10
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  • 11
    Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and 2 schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003; 21: 92-98.
  • 12
    Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 meta-analyses of updated individual data. MACH-NC Collaborative Group meta-analysis of chemotherapy on head and neck cancer. Lancet. 2000; 355: 949-955.
  • 13
    Blanchard P, Baujart B, Holostenco V, et al; MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011; 100: 33-40.
  • 14
    Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC and RTOG. Head Neck. 2005; 27: 843-850.
  • 15
    Wolf GT, Hong WK, Fisher SG, et al; The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; 324: 1685-1690.
  • 16
    Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994; 86: 265-272.
  • 17
    Hristov B, Bajaj G. Radiotherapeutic management of laryngeal carcinoma. Otolaryngol Clin North Am. 2008; 41: 715-740.
  • 18
    Tufano RP, Stafford EM. Organ preservation surgery for laryngeal cancer. Otolaryngol Clin North Am. 2008; 41: 741-755.
  • 19
    Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357: 1705-1715.
  • 20
    Pignon AP, le Maitre A, Maillard E, Bourhis J; MACH-NC Collaborative Groups. Meta-analysis in head and neck cancer (MACH-NC): an update on 93 randomized trials and 17,346 patients. Radiat Oncol. 2009; 92: 4-14.
  • 21
    Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2008 [based on November 2010 SEER data submission, posted to the SEER website 2011]. Bethesda, MD: National Cancer Institute; 2011. Available from: Accessed January 3, 2012.
  • 22
    Suarez-Cunqueriro MMS, Schramm A, Schoin R, et al. Speech and swallowing impairment after treatment for oral and oropharyngeal cancer. Arch Otolaryngol Head Neck Surg. 2008; 143: 1290-1304.
  • 23
    Yao M, Dornfeld KJ, Buatti JM, et al. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma—the University of Iowa experience. Int J Radiat Oncol Biol Phys. 2005; 63: 410-421.